[Stevens-Johnson syndrome/toxic epidermal necrolysis].
Watanabe
Hideaki
H
Department of Dermatology, Showa University School of Medicine.
Iijima
Masafumi
M
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D064420:Drug-Related Side Effects and Adverse Reactions; D005938:Glucocorticoids / Q000008:administration & dosage; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007371:Interferon-gamma; D010956:Plasmapheresis; D012015:Reference Standards; D013262:Stevens-Johnson Syndrome / Q000139:chemically induced* / Q000175:diagnosis / Q000209:etiology* / Q000473:pathology / Q000628:therapy; D013997:Time Factors; D014409:Tumor Necrosis Factor-alpha
D000900:Anti-Bacterial Agents; D005938:Glucocorticoids; D016756:Immunoglobulins, Intravenous; D014409:Tumor Necrosis Factor-alpha; D007371:Interferon-gamma